Christophe Pierre Weber

CIK: 0002011270

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TAK

TAKEDA PHARMACEUTICAL CO LTD

DirectorOfficer

BSX

BOSTON SCIENTIFIC CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

BSX
BOSTON SCIENTIFIC CORP
May 7, 2026
Award(A)
Direct
1.8K shares-
BSX
BOSTON SCIENTIFIC CORP
May 7, 2026
Award(A)
Direct
1.1K shares-
TAK
TAKEDA PHARMACEUTICAL CO LTD
Apr 27, 2026
Award(A)
Direct
78.9K shares-
TAK
TAKEDA PHARMACEUTICAL CO LTD
Apr 27, 2026
Award(A)
Direct
165.4K shares-
BSX
BOSTON SCIENTIFIC CORP
Mar 2, 2026
Award(A)
Direct
556 shares-
BSX
BOSTON SCIENTIFIC CORP
Mar 2, 2026
Award(A)
Direct
323 shares-

		Type	Shares	Price		Ownership
May 7, 2026	BSX BOSTON SCIENTIFIC CORP	Award(A)	1,767	-	$0	Direct
May 7, 2026	BSX BOSTON SCIENTIFIC CORP	Award(A)	1,140	-	$0	Direct
Apr 27, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	78,900	-	$0	Direct
Apr 27, 2026	TAK TAKEDA PHARMACEUTICAL CO LTD	Award(A)	165,370	-	$0	Direct
Mar 2, 2026	BSX BOSTON SCIENTIFIC CORP	Award(A)	556	-	$0	Direct
Mar 2, 2026	BSX BOSTON SCIENTIFIC CORP	Award(A)	323	-	$0	Direct

1-6 of 6 transactions

About Weber Christophe Pierre

Weber Christophe Pierre (SEC CIK 0002011270) files insider reports with the SEC as President and CEO of TAKEDA PHARMACEUTICAL CO LTD (TAK) and Director of BOSTON SCIENTIFIC CORP (BSX).

Signal8 holds 5 ownership filings by Weber Christophe Pierre (2 Form 3, 3 Form 4), filed between Feb 24, 2026 and May 11, 2026. Those filings report 6 transactions, from Mar 2, 2026 to May 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Weber Christophe Pierre's filings is in TOKYO.

Recent filings by Weber Christophe Pierre

May 7, 2026: Grants or awards of BSX shares (2 lines, Form 4, code A).
Apr 27, 2026: Grants or awards of TAK shares (2 lines, Form 4, code A).
Mar 2, 2026: Grants or awards of BSX shares (2 lines, Form 4, code A).

Other insiders filing for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Duprey Lauren Rusckowski, Chief Transformation Officer
Plump Andrew Stewart, President, R&D
Greenway Nicola Deidre Petal, Chief Human Resources Officer
Farajallah Awny Samaan Botros, Chief Medical Officer
Ibrahim Ramy Riad Ahmed, President, PDT BU
Pacheco Rhonda Janice, President, U.S. Business Unit

How to read Form 4 transaction codes